摘要
目的:评估瑞戈非尼联合PD-1抑制剂治疗对中晚期直肠癌患者生存率、疾病相关因子水平及不良反应的影响。方法:选取2019年1月至2020年12月蚌埠医科大学第一附属医院收治的80例中晚期直肠癌患者,采用随机数字表法分为试验组(瑞戈非尼联合PD-1抑制剂,40例)和对照组(瑞戈非尼单药,40例)。主要观察指标包括治疗效果、疾病相关因子(脂肪酸合成酶(FAS)、肿瘤M2型丙酮酸激酶(TuM2-PK)、表皮生长因子(EGF)、白细胞介素-17(IL-17)、胰岛素样生长因子1(IGF-1)、肿瘤坏死因子α(TNF-α))水平、生存率及不良反应发生率。结果:试验组患者的客观缓解率显著高于对照组(P<0.05)。治疗后2组患者的FAS、TuM2-PK、EGF、IL-17、IGF-1、TNF-α水平均显著降低(P<0.05),且试验组患者各项疾病相关因子水平均显著低于对照组(P<0.05)。试验组患者治疗后1年、2年的生存率显著高于对照组(P<0.05),3年生存率高于对照组,但差异无统计学意义(P>0.05)。2组患者主要不良反应包括胃肠道反应、肝功能异常、肾功能异常、皮肤反应以及出血风险,各项不良反应发生率差异无统计学意义(P>0.05)。结论:瑞戈非尼联合PD-1抑制剂治疗可显著提高中晚期直肠癌患者的客观缓解率和生存率,降低疾病相关因子水平,且不增加不良反应发生率,具有较好的临床应用前景。
Objective:To evaluate the effect of regorafenib in combination with PD-1 inhibitor on survival rates,levels of diseaserelated factors,and adverse reactions in patients with advanced rectal cancer.Methods:Eighty patients with advanced rectal cancer admitted to the First Affiliated Hospital of Bengbu Medical University from January 2019 to December 2020 were selected and divided into the experimental group(regorafenib combined with PD-1 inhibitor,40 cases)and the control group(regorafenib monotherapy,40 cases)by the random number table method.The primary observed indicators include treatment efficacy,levels of disease-related factors(fatty acid synthetase(FAS),tumor M2-type pyruvate kinase(TuM2-PK),epidermal growth factor(EGF),interleukin-17(IL-17),insulin-like growth factor 1(IGF-1),tumor necrosis factorα(TNF-α)),survival rates,and incidence of adverse reactions.Results:The objective response rate of patients in the experimental group was significantly higher than that in the control group(P<0.05).After treatment,the levels of FAS,TuM2-PK,EGF,IL-17,IGF-1 and TNF-αin both groups were significantly decreased(P<0.05),and the levels of various disease-related factors in the experimental group were significantly higher than those in the control group(P<0.05).The survival rates of patients in the experimental group at 1 year and 2 years after treatment were significantly higher than those in the control group(P<0.05),and the 3-year survival rate was higher than that in the control group,but the difference was not statistically significant(P>0.05).The main adverse reactions of patients in both groups included gastrointestinal symptoms,abnormal liver function,abnormal renal function,skin reactions and bleeding risk.There was no statistically significant difference in the incidence of each adverse reaction(P>0.05).Conclusion:Regorafenib in combination with PD-1 inhibitor significantly improves the objective response rate and survival rates,reduces levels of disease-related factors,and does not increase the incidence of adverse reactions in patients with advanced rectal cancer,showing good clinical application prospects.
作者
张露
韩正全
章海斌
高振远
Zhang Lu;Han Zhengquan;Zhang Haibin;Gao Zhenyuan(Department of Oncology,The First Affiliated Hospital of Bengbu Medical University,Bengbu,Anhui 233000,China)
出处
《大理大学学报》
2025年第8期57-61,共5页
Journal of Dali University
基金
蚌埠医科大学科技项目(2023byzd092)
安徽省高等学校自然科学研究项目(KJ2021A0690)。
作者简介
第一作者:张露,主治医师,主要从事恶性肿瘤的个体化治疗研究;通信作者:高振远,主任医师,E-mail:ga013645529859@163.com。
